Stereotactic radiotherapy for stage I non-small-cell lung cancer—the triumph of technology over biology?
David Ball* and H Rodney Withers
Correspondence *Division of Radiation Oncology, Peter MacCallum Cancer Centre, St Andrew's Place, East Melbourne, Victoria 3002, Australia
Email david.ball@petermac.org
Should patients with stage I non-small-cell lung cancer who are unsuitable for surgery receive hypofractionated stereotactic radiotherapy? In the rush to implement new technology, there could be a danger of overlooking refinements important to ensure safety, according to the author of this Viewpoint.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.